Skip to main content

Table 1 Patients’ characteristics at prioritization according to outcome

From: Creatinine-lactate score predicts mortality in non-acetaminophen-induced acute liver failure in patients listed for liver transplantation

Variables LT group
n = 69
Non-LT group
n = 31
p value
Age: mean ± SD, y 34.5 ± 13.7 37.7 ± 16.8 0.5000
Sex women: n (%) 51 (73.9) 27 (87.1) 0.1937
Encephalopathy: n (%)    
Grades I/II 10 (14.7) 10 (32.2) 0.0592
Grade III/IV 58 (85.3) 21 (67.8)  
Etiology: n (%)    
A or B or C virus 13 (18.8) 4 (12.9) 0.3368
DILI 21 (30.4) 11 (35.5) 0.6479
Autoimmune hepatitis 14 (20.3) 1 (3.2)* 0.0212
Indeterminate 17 (24.6) 14 (45.2)* 0.0358
Wilson’s disease 2 (2.9) 2 (6.5) 0.5858
Budd-Chiari syndrome 1 (1.5) 0 1.0000
Jaundice-encephalopathy interval: n (%)    
≤ 7 days 18 (28.1) 4 (16.0) 0.1803
> 7 and ≤ 28 days 28 (43.8) 13 (52.0) 0.3204
> 28 days 18 (28.1) 8 (32.0) 0.7970
Waiting list time: median (min–max), days 1 (0–9) 2 (0–7) 0.5020
INR: mean ± SD 5.09 ± 2.77 6.47 ± 3.90 0.1600
AST: mean ± SD, U/L 578 ± 578 493 ± 779 0.0590
Bilirubin: mean ± SD, mg/dL 28.31 ± 10.06 29.34 ± 11.44 0.6690
Creatinine: mean ± SD, mg/dL 1.55 ± 1.54 2.59 ± 2.34* 0.0020
Lactate: mean ± SD, mg/dL 40.35 ± 29.28 78.43 ± 48.27* < 0.0001
MELD 38.3 ± 8.0 44.1 ± 8.0* 0.0010
BiLE score 10.3 ± 4.1 15.8 ± 5.5* < 0.0001
Creatinine-Lactate score 160.4 ± 94.8 296.1 ± 131.0* < 0.0001
  1. LT group, liver transplant group; Non-LT group, patients died before LT; DILI, drug induced live injury; MELD, model for end-stage liver disease; BiLE score, bilirubin lactate etiology score; *p < 0.05 compared to LT group